【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 10
2.1 What Is This Report About? 10
2.2 Peripheral Vascular Procedures, Segmentation 10
2.3 Definitions of Procedures Covered in the Report 11
3 Peripheral Vascular Procedures, Asia-Pacific 15
3.1 Peripheral Vascular Procedures, Asia-Pacific, 2007-2021 15
3.2 Peripheral Vascular Procedures, Asia-Pacific, 2007-2014 17
3.3 Peripheral Vascular Procedures, Asia-Pacific, 2014-2021 20
4 Peripheral Vascular Procedures, Australia 23
4.1 Peripheral Vascular Procedures, Australia, 2007-2014 23
4.2 Peripheral Vascular Procedures, Australia, 2014-2021 26
4.2.1 Aortic Open Repair Procedures, Australia, 2007-2014 29
4.2.2 Aortic Stent Graft Procedures, Australia, 2007-2014 31
4.2.3 Deep Seated Artery Stenting Procedures, Australia, 2007-2014 33
4.2.4 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, Australia, 2007-2014 35
4.2.5 Peripheral Vascular Stenting Procedures, Australia, 2007-2014 37
4.2.5.1 Iliac Artery Stenting Procedures, Australia, 2007-2014 39
4.2.5.2 Femoropopliteal Artery Stenting Procedures, Australia, 2007-2014 41
4.2.5.3 Infrapopliteal Artery Stenting Procedures, Australia, 2007-2014 43
4.2.6 PTA Drug Eluting Balloon (DEB) Procedures, Australia, 2007-2014 45
4.2.7 Aortic Open Repair Procedures, Australia, 2014-2021 47
4.2.8 Aortic Stent Graft Procedures, Australia, 2014-2021 49
4.2.9 Deep Seated Artery Stenting Procedures, Australia, 2014-2021 51
4.2.10 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, Australia, 2014-2021 53
4.2.11 Peripheral Vascular Stenting Procedures, Australia, 2014-2021 55
4.2.11.1 Iliac Artery Stenting Procedures, Australia, 2014-2021 57
4.2.11.2 Femoropopliteal Artery Stenting Procedures, Australia, 2014-2021 59
4.2.11.3 Infrapopliteal Artery Stenting Procedures, Australia, 2014-2021 61
4.2.12 PTA Drug Eluting Balloon (DEB) Procedures, Australia, 2014-2021 63
5 Peripheral Vascular Procedures, China 65
5.1 Peripheral Vascular Procedures, China, 2007-2014 65
5.2 Peripheral Vascular Procedures, China, 2014-2021 68
5.2.1 Aortic Open Repair Procedures, China, 2007-2014 71
5.2.2 Aortic Stent Graft Procedures, China, 2007-2014 73
5.2.3 Deep Seated Artery Stenting Procedures, China, 2007-2014 75
5.2.4 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, China, 2007-2014 77
5.2.5 Peripheral Vascular Stenting Procedures, China, 2007-2014 79
5.2.5.1 Iliac Artery Stenting Procedures, China, 2007-2014 81
5.2.5.2 Femoropopliteal Artery Stenting Procedures, China, 2007-2014 83
5.2.5.3 Infrapopliteal Artery Stenting Procedures, China, 2007-2014 85
5.2.6 Aortic Open Repair Procedures, China, 2014-2021 87
5.2.7 Aortic Stent Graft Procedures, China, 2014-2021 89
5.2.8 Deep Seated Artery Stenting Procedures, China, 2014-2021 91
5.2.9 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, China, 2014-2021 93
5.2.10 Peripheral Vascular Stenting Procedures, China, 2014-2021 95
5.2.10.1 Iliac Artery Stenting Procedures, China, 2014-2021 97
5.2.10.2 Femoropopliteal Artery Stenting Procedures, China, 2014-2021 99
5.2.10.3 Infrapopliteal Artery Stenting Procedures, China, 2014-2021 101
5.2.11 PTA Drug Eluting Balloon (DEB) Procedures, China, 2014-2021 103
6 Peripheral Vascular Procedures, India 105
6.1 Peripheral Vascular Procedures, India, 2007-2014 105
6.2 Peripheral Vascular Procedures, India, 2014-2021 108
6.2.1 Aortic Open Repair Procedures, India, 2007-2014 111
6.2.2 Aortic Stent Graft Procedures, India, 2007-2014 113
6.2.3 Deep Seated Artery Stenting Procedures, India, 2007-2014 115
6.2.4 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, India, 2007-2014 117
6.2.5 Peripheral Vascular Stenting Procedures, India, 2007-2014 119
6.2.5.1 Iliac Artery Stenting Procedures, India, 2007-2014 121
6.2.5.2 Femoropopliteal Artery Stenting Procedures, India, 2007-2014 123
6.2.5.3 Infrapopliteal Artery Stenting Procedures, India, 2007-2014 125
6.2.6 PTA Drug Eluting Balloon (DEB) Procedures, India, 2007-2014 127
6.2.7 Aortic Open Repair Procedures, India, 2014-2021 129
6.2.8 Aortic Stent Graft Procedures, India, 2014-2021 131
6.2.9 Deep Seated Artery Stenting Procedures, India, 2014-2021 133
6.2.10 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, India, 2014-2021 135
6.2.11 Peripheral Vascular Stenting Procedures, India, 2014-2021 137
6.2.11.1 Iliac Artery Stenting Procedures, India, 2014-2021 139
6.2.11.2 Femoropopliteal Artery Stenting Procedures, India, 2014-2021 141
6.2.11.3 Infrapopliteal Artery Stenting Procedures, India, 2014-2021 143
6.2.12 PTA Drug Eluting Balloon (DEB) Procedures, India, 2014-2021 145
7 Peripheral Vascular Procedures, Japan 147
7.1 Peripheral Vascular Procedures, Japan, 2007-2014 147
7.2 Peripheral Vascular Procedures, Japan, 2014-2021 150
7.2.1 Aortic Open Repair Procedures, Japan, 2007-2014 153
7.2.2 Aortic Stent Graft Procedures, Japan, 2007-2014 155
7.2.3 Deep Seated Artery Stenting Procedures, Japan, 2007-2014 157
7.2.4 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, Japan, 2007-2014 159
7.2.5 Peripheral Vascular Stenting Procedures, Japan, 2007-2014 161
7.2.5.1 Iliac Artery Stenting Procedures, Japan, 2007-2014 163
7.2.5.2 Femoropopliteal Artery Stenting Procedures, Japan, 2007-2014 165
7.2.5.3 Infrapopliteal Artery Stenting Procedures, Japan, 2007-2014 167
7.2.6 Aortic Open Repair Procedures, Japan, 2014-2021 169
7.2.7 Aortic Stent Graft Procedures, Japan, 2014-2021 171
7.2.8 Deep Seated Artery Stenting Procedures, Japan, 2014-2021 173
7.2.9 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, Japan, 2014-2021 175
7.2.10 Peripheral Vascular Stenting Procedures, Japan, 2014-2021 177
7.2.10.1 Iliac Artery Stenting Procedures, Japan, 2014-2021 179
7.2.10.2 Femoropopliteal Artery Stenting Procedures, Japan, 2014-2021 181
7.2.10.3 Infrapopliteal Artery Stenting Procedures, Japan, 2014-2021 183
7.2.11 PTA Drug Eluting Balloon (DEB) Procedures, Japan, 2014-2021 185
8 Peripheral Vascular Procedures, South Korea 187
8.1 Peripheral Vascular Procedures, South Korea, 2007-2014 187
8.2 Peripheral Vascular Procedures, South Korea, 2014-2021 190
8.2.1 Aortic Open Repair Procedures, South Korea, 2007-2014 193
8.2.2 Aortic Stent Graft Procedures, South Korea, 2007-2014 195
8.2.3 Deep Seated Artery Stenting Procedures, South Korea, 2007-2014 197
8.2.4 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, South Korea, 2007-2014 199
8.2.5 Peripheral Vascular Stenting Procedures, South Korea, 2007-2014 201
8.2.5.1 Iliac Artery Stenting Procedures, South Korea, 2007-2014 203
8.2.5.2 Femoropopliteal Artery Stenting Procedures, South Korea, 2007-2014 205
8.2.5.3 Infrapopliteal Artery Stenting Procedures, South Korea, 2007-2014 207
8.2.6 Aortic Open Repair Procedures, South Korea, 2014-2021 209
8.2.7 Aortic Stent Graft Procedures, South Korea, 2014-2021 211
8.2.8 Deep Seated Artery Stenting Procedures, South Korea, 2014-2021 213
8.2.9 Percutaneous Transluminal Angioplasty (PTA) Balloon Procedures, South Korea, 2014-2021 215
8.2.10 Peripheral Vascular Stenting Procedures, South Korea, 2014-2021 217
8.2.10.1 Iliac Artery Stenting Procedures, South Korea, 2014-2021 219
8.2.10.2 Femoropopliteal Artery Stenting Procedures, South Korea, 2014-2021 221
8.2.10.3 Infrapopliteal Artery Stenting Procedures, South Korea, 2014-2021 223
8.2.11 PTA Drug Eluting Balloon (DEB) Procedures, South Korea, 2014-2021 225
9 Appendix 227
9.1 Research Methodology 228
9.1.1 Coverage 228
9.1.2 Secondary Research 228
9.1.3 Primary Research 229
9.1.4 Market Modeling and Forecasting 230
9.1.5 Company Share Analysis 233
9.1.6 Distribution Share Analysis 234
9.2 Expert Panel 235
9.3 GlobalData Consulting 235
9.4 Contact Us 235
9.5 Disclaimer 235
【レポート販売概要】
■ タイトル：アジアの末梢血管処置用機器市場見通し（～2021）■ 英文：Asia-Pacific Peripheral Vascular Procedures Outlook to 2021
■ 発行日：2016年4月7日
■ 調査会社：GlobalData
■ 商品コード：GDMECR0209PDB
■ 調査対象地域：アジア太平洋
- 乳製品ホワイトナーの世界市場2016-2020About Dairy Whiteners Dairy whiteners are widely used as a substitute for fresh milk in tea; coffee; hot chocolate; and other food products such as soups, sauces, puddings, and cereal dishes. These are available in fluid, and dried. The production of dairy whiteners has gone up owing to their being convenient, shelf stable, and ready to reconstitute. The main ingredients of dairy products are: • P …
- Pacific Rubiales Energy Corp.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Pacific Rubiales Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Pacific Rubiales Energy Corp. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an …
- CSL-654 (Hemophilia A and B)：市場予測と分析（～2022）CSL-654 (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through …
- 世界のモバイルNANDフラッシュメモリ市場動向（2014-2018）TechNavio’s analysts forecast the Global Mobile NAND Flash Memory market to grow at a CAGR of 18.8 percent over the period 2013-2018. One of the key factors contributing to this market growth is the high demand for smartphones across the globe. The Global Mobile NAND Flash Memory has also been witnessing the rapid technological advancements. However, the high inventory levels in the supply chain c …
- マルチプレックス・アッセイの世界市場：キット、試薬、パネル、核酸塩系、蛋白質系The multiplex assays market is projected to reach USD 3.76 Billion by 2021 from USD 2.66 Billion in 2016, growing at a CAGR of 7.2% during the forecast period (2016–2021). Need for effective analytical platforms in research to reduce operational costs, adoption of companion diagnostics for increasing efficacy of therapies, and advantages of multiplexing over traditional assays are the major driver …
- びまん性大細胞型B細胞性リンパ腫：世界の臨床試験レビュー（2014年上半期）Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overv …
- CRMにおけるビックデータ（Big Data in Customer Relationship Management (CRM)）Customer Relationship Management (CRM) is a model of managing relationship and interaction between company and customer. This includes using technology for organizing, automating, and synchronizing all customer-related information like sales, marketing, services, support and more. Big Data represents more than just a collection of data sets that form a large quantity of data, which is difficult to …
- ブラジル・ロシア・インド・中国の小関節手術動向（～2020）BRIC Small Joints Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Small Joints Procedures Outlook to 2020", provides key procedures data on the BRIC Small Joints Procedures. The report provides procedure volumes within market segments - Ankle Replacement Procedures, Elbow Replacement Procedures, Digits Replacement Procedures and Wrist Replacement Procedures. The data in the repor …
- 医療用フォームの世界市場予測（～2026）：材料種類別（ポリウレタン、ポリスチレン、ポリオレフィン）、形状別（フレキシブル、リジッド、スプレー）、用途別、地域別The global medical foam market is projected to reach USD 30.89 Billion by 2026, at a CAGR of 8.2% from 2016 to 2026. The major factors expected to drive the demand for medical foam during the forecast period include, increasing aging population, increased shift towards technologically advanced products, and others. Another factor expected to drive the market is the increased healthcare expenditure …
- 世界のビデオCDN市場動向（2012-2016）TechNavio's analysts forecast the Global Video Content Delivery Network (CDN) market to grow at a CAGR of 40.61 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased streaming of video data. The Global Video CDN market has also been witnessing the development of content delivery clouds. However, the high cost of video CDNs could pose a challe …
- ビタミン成分の世界市場：ビタミンB、ビタミンK、ビタミンC、ビタミンD、ビタミンE、ビタミンAAbout Vitamins Vitamins are of two sorts — water soluble (A, D, E, and K) and fat soluble (vitamin B and vitamin C). Vitamin B can be of the following types B1 (thiamine), B2(riboflavin), B3 (niacin), B5 (pantothenic), B6, B12, B9, and B7. The chemical ingredients that constitute vitamins are called vitamers. Vitamins can contain multiple vitamers. For example, Vitamin A contains six vitamers — re …
- 溶融亜鉛メッキ鋼管のインド市場2017-2021ABSTRACTAbout Galvanized Steel Tubes The galvanized steel tubes market in India is primarily driven by the rapid industrialization, leading to increasing investments in building and construction activities in the country. The economy of India is growing at a significant rate, which is likely to impact the galvanized steel tubes market in the country. In India, the process industries, as well as th …
- 世界の脳機能モニタリング装置市場Global brain monitoring device market provides quality treatment to patients suffering from brain and related diseases such as brain tumor, epilepsy, sleep disorder and so on. The technological advancement and innovations in medical device and treatment enable to provide quality brain monitoring services to patients. The global market value of the Global brain monitoring device market is expected …
- 脂肪性肝疾患(Fatty Liver Disease)：世界の治験レビュー（2015年上半期版）Fatty Liver Disease Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Fatty Liver Disease Global Clinical Trials Review, H1, 2015" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recru …
- がん化学療法による悪心・嘔吐（CINV）治療薬の世界市場2017-2021About CINV Drugs The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the pati …
